<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5888">
  <stage>Registered</stage>
  <submitdate>25/02/2015</submitdate>
  <approvaldate>25/02/2015</approvaldate>
  <nctid>NCT02392559</nctid>
  <trial_identification>
    <studytitle>Trial Assessing Efficacy, Safety and Tolerability of PCSK9 Inhibition in Paediatric Subjects With Genetic LDL Disorders</studytitle>
    <scientifictitle>Double-blind, Randomized, Multicenter, Placebo-Controlled Study to Characterize the Efficacy, Safety, and Tolerability of 24 Weeks of Evolocumab for LDL-C Reduction in Pediatric Subjects 10 to 17 Years of Age With HeFH</scientifictitle>
    <utrn />
    <trialacronym>HAUSER-RCT</trialacronym>
    <secondaryid>2014-002277-11</secondaryid>
    <secondaryid>20120123</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Heterozygous Familial Hypercholesterolemia</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Evolocumab
Treatment: drugs - Placebo

Experimental: QM evolocumab - Evolocumab subcutaneous injection every 4 weeks (QM)

Placebo Comparator: Placebo - Matching subcutaneous injection every 4 weeks (QM)


Treatment: drugs: Evolocumab
Dose of subcutaneous Evolocumab every 4 weeks

Treatment: drugs: Placebo
Dose of subcutaneous placebo treatment every 4 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage change from baseline in low density lipoprotein-cholesterol levels - Same as outcome measure</outcome>
      <timepoint>Week 24</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in LDL-C levels - Same as outcome measure</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage change from baseline in apoliprotein-b (ApoB) - Same as outcome measure</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage change from baseline in total cholesterol:HDL-C ratio - Same as outcome measure</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in ApoB:ApoA1 ratio - The change in ApoB:ApoA1 ratio between baseline and week 24</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage change in from baseline in non-HDL-C - Same as outcome measure</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean percentage change from baseline in low density lipoprotein-cholesterol levels at week 22 and week 24 - Same as outcome measure</outcome>
      <timepoint>Weeks 22 and 24</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male or female = 10 to = 17 years of age (before 18th birthday)

          -  Diagnosis of heterozygous familial hypercholesterolemia

          -  On an approved statin with stable optimized dose for = 4 weeks

          -  Other lipid-lowering therapy stable for = 4 weeks (fibrates must be stable for = 6
             weeks)

          -  Fasting LDL-C = 130 mg/dL (3.4 mmol/L)

          -  Fasting triglycerides = 400 mg/dL (4.5 mmol/L)</inclusivecriteria>
    <inclusiveminage>10</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>17</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Type 1 diabetes, or type 2 diabetes that is or poorly controlled

          -  Uncontrolled hyperthyroidism or hypothyroidism

          -  Cholesterylester transfer protein (CETP) inhibitor in the last 12 months, or
             mipomersen or lomitapide in the last 5 months

          -  Previously received evolocumab or any other investigational therapy to inhibit PCSK9.

          -  Lipid apheresis within the last 12 weeks prior to screening.

          -  Homozygous Familial Hypercholesterolemia</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>24/03/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>150</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>21/06/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Research Site - Camperdown</hospital>
    <postcode>2050 - Camperdown</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Delaware</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Feldkirch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>La Louvière</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>São Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Atlántico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Ostrava-Poruba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha 5</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Svitavy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Helsinki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Kuopio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Thessaloniki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Palermo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pisa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Torino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Oslo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Western Cape</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Andalucía</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Cataluña</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Galicia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Geneva 14</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Reinach</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Ankara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Izmir</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Amgen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>A study to assess safety and efficacy of evolocumab (AMG-145) in paediatric subjects aged
      10-17 years diagnosed with heterozygous familial hypercholesterolemia.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02392559</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>MD</name>
      <address>Amgen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Amgen Call Center</name>
      <address />
      <phone>866-572-6436</phone>
      <fax />
      <email>medinfo@amgen.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>